Evaluation of a new antinauseant drug for the prevention of motion sickness.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004780:Environment, Controlled; D004809:Ephedrine / Q000494:pharmacology; D006801:Humans; D008297:Male; D008468:Meclizine / Q000494:pharmacology; D009041:Motion Sickness / Q000188:drug therapy* / Q000517:prevention & control; D010919:Placebos; D011398:Promethazine / Q000494:pharmacology; D012399:Rotation; D012601:Scopolamine / Q000494:pharmacology
D000932:Antiemetics; D010919:Placebos; D008468:Meclizine; D012601:Scopolamine; D011398:Promethazine; D004809:Ephedrine